Balyasny Asset Management’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.33M | Buy |
+162,812
| New | +$1.33M | ﹤0.01% | 1302 |
|
|
2025
Q1 | – | Sell |
-58,194
| Closed | -$867K | – | 2341 |
|
|
2024
Q4 | $867K | Buy |
58,194
+9,614
| +20% | +$143K | ﹤0.01% | 1319 |
|
|
2024
Q3 | $743K | Buy |
+48,580
| New | +$743K | ﹤0.01% | 1411 |
|
|
2024
Q1 | – | Sell |
-515,453
| Closed | -$9.85M | – | 2355 |
|
|
2023
Q4 | $9.85M | Buy |
515,453
+51,003
| +11% | +$974K | 0.02% | 636 |
|
|
2023
Q3 | $8.34M | Sell |
464,450
-1,402,266
| -75% | -$25.2M | 0.02% | 659 |
|
|
2023
Q2 | $37.9M | Buy |
+1,866,716
| New | +$37.9M | 0.08% | 273 |
|
|
2023
Q1 | – | Sell |
-22,025
| Closed | -$455K | – | 2562 |
|
|
2022
Q4 | $455K | Buy |
+22,025
| New | +$455K | ﹤0.01% | 1458 |
|
|
2022
Q3 | – | Sell |
-408,122
| Closed | -$10.3M | – | 2689 |
|
|
2022
Q2 | $10.3M | Buy |
+408,122
| New | +$10.3M | 0.03% | 523 |
|
|
2022
Q1 | – | Sell |
-149,730
| Closed | -$6.06M | – | 2424 |
|
|
2021
Q4 | $6.06M | Buy |
149,730
+84,857
| +131% | +$3.43M | 0.02% | 665 |
|
|
2021
Q3 | $2.26M | Sell |
64,873
-1,774
| -3% | -$61.9K | 0.01% | 893 |
|
|
2021
Q2 | $1.83M | Sell |
66,647
-217,879
| -77% | -$5.98M | 0.01% | 935 |
|
|
2021
Q1 | $7.99M | Buy |
284,526
+231,205
| +434% | +$6.49M | 0.04% | 463 |
|
|
2020
Q4 | $1.38M | Buy |
+53,321
| New | +$1.38M | 0.01% | 798 |
|
|
2020
Q2 | – | Sell |
-151,677
| Closed | -$2.11M | – | 1259 |
|
|
2020
Q1 | $2.11M | Buy |
+151,677
| New | +$2.11M | 0.03% | 514 |
|